RxDoctor Payments Data

Deborah Goldstein

Infectious Disease · Washington, DCNPI 1457502460

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $946 of the $1,350 with a category attached, or 70.1%. Merck accounts for 98.6% of it on its own, with 1 other manufacturer making up the rest.

$1,350in general payments, 2019–2025

Across 13 payments — averaging $103.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1K
  • Ferring Pharmaceuticals Inc.$18
$706,669in research payments, 2019–2025

Across 261 payments — averaging $2707.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$224K
  • Merck$223K
  • Viiv Healthcare Company$205K
  • Amgen$27K
  • Janssen Research & Development, LLC$23K
  • GSK$5K

What the payments were for

  • Travel & lodging$94670%
  • Food & beverage$40430%

General payments by program year

20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck12$1,332
Ferring Pharmaceuticals Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,350 in reported general payments places this provider in the 70th percentile of 74 infectious disease providers in District of Columbia.

See all infectious disease providers in District of Columbia

Other infectious disease in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →